Signal from the log
Estuary Biotherapeutics
93 M$ · Series A · United States
Estuary développe des thérapies géniques injectées directement dans le rein contre la polykystose rénale autosomique dominante, qui détruit les reins par des kystes. Série A de 93 M$ menée par RA Capital, 103 M$ avec la seed ; le Form D déclare 40,7 M$ effectivement placés, première vente le 1er juillet.
Verified
Announced on , logged by the watch of 16 October 2026.
- Operation
- Funding round
- Announced amount
- 93 M$
- Stage
- Series A
- Country
- United States
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by RA Capital Management , with Deep Track Capital , Biogen New Ventures , UPMC Enterprises , Pivotal bioVenture Partners , National Kidney Foundation Innovation Fund , 4BIO Capital , GV
Provenance
Logged on 16 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.